LON:COG Cambridge Cognition (COG) Share Forecast, Price & News GBX 71.50 -23.30 (-24.58%) (As of 04:06 PM ET) Add Compare Share Share Today's Range 71.50▼ 8050-Day Range 90.50▼ 9852-Week Range 71.50▼ 129.74Volume855,224 shsAverage Volume51,127 shsMarket Capitalization£24.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsInsider TradesHeadlinesOptions ChainProfileChartCompetitorsInsider TradesHeadlinesOptions Chain About Cambridge Cognition (LON:COG) StockCambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency. It also provides CANTAB Connect Research, a proprietary platform that provides insights into behaviours, underlying brain circuits, and measurement of digital cognitive biomarkers; CANTAB Mobile, a touchscreen assessment of memory, mood, and functional status to detect the earliest signs of clinically relevant memory problems; CANTAB Insight to assess cognitive health; and CANTAB BrainHealth for assessing workplace wellbeing. In addition, the company offers electronic questionnaires and scales, a digital bespoke questionnaire; NeuroVocalix, a voice analysis platform to analyze voice to assess neurological change; cognition kit, a high frequency testing kit to detect changes over time and day-to-day cognition with short regular tests using patients' own devices. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.Read More COG Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COG Stock News HeadlinesSeptember 26, 2023 | lse.co.ukCambridge Cognition swings to interim loss amid ballooning costsSeptember 26, 2023 | marketwatch.comCambridge Cognition Shares Fall on Swing to Pretax Loss; Secures GBP3 Mln LoanSeptember 26, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 25, 2023 | msn.comWhy Gouda is good for you – healthy cheeses and the ones to avoidSeptember 25, 2023 | mirror.co.ukEarly childhood reading brings 'lifelong rewards' and is tied to better mental healthSeptember 25, 2023 | msn.comExperts: Shawn Fain's biting style is creating a moment, just like another UAW labor iconSeptember 25, 2023 | markets.businessinsider.comLEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in JapanSeptember 22, 2023 | msn.comPsychotherapists Flip Freudian Thinking on Treating DepressionSeptember 26, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 22, 2023 | msn.comSuppressing negative thoughts may actually be a good thingSeptember 22, 2023 | americanbankingnews.comCambridge Cognition (LON:COG) Share Price Passes Below Two Hundred Day Moving Average of $98.74September 21, 2023 | msn.comHaving negative thoughts? Here’s how to suppress them to improve mental healthSeptember 20, 2023 | msn.comSuppressing negative emotions may actually benefit your mental heath, study findsSeptember 20, 2023 | msn.comSuppressing negative thoughts may be good for mental health, study suggestsSeptember 20, 2023 | msn.comA stiff upper lip could make you happierSeptember 20, 2023 | msn.comScientists Dispute Depression Theory on Suppressing Negative ThoughtsSeptember 20, 2023 | msn.comDon't let it out? Suppressing negative thoughts is good for your mental healthSeptember 20, 2023 | msn.comThermo Fisher just opened a $180 million plant. Executives already are talking about expanding.September 19, 2023 | msn.comBest magnesium supplements to boost your overall health in 2023September 19, 2023 | theguardian.comJustice for Neanderthals! What the debate about our long-dead cousins reveals about usSeptember 15, 2023 | msn.com7 healthy lifestyle changes that could help reduce risk of depression, says study: ‘Enormous benefits’September 15, 2023 | bizjournals.comSage Therapeutics to lose 95 employees in Cambridge in mass layoffSeptember 14, 2023 | theguardian.comThe Guardian view on class in Britain: the government doesn’t want to talk about itSeptember 13, 2023 | msn.com7 lifestyle factors that reduce the risk of depression, according to new studySeptember 13, 2023 | msn.comSeven lifestyle changes that lower risk of depressionSeptember 12, 2023 | msn.com7 simple habits that could lower your risk of depression, even if it runs in your familySeptember 12, 2023 | msn.comHealthy lifestyle ‘key for preventing depression – regardless of genetic risk’See More Headlines Receive COG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cambridge Cognition and its competitors with MarketBeat's FREE daily newsletter. Email Address COG Company Calendar Last Earnings9/22/2020Today9/26/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Health Information Services Sub-IndustryN/A SectorMedical Current SymbolLON:COG CUSIPN/A CIKN/A Webwww.cambridgecognition.com Phone44 1223 810 700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E Ratio56.96 P/E GrowthN/ANet IncomeN/A Net Margins-3.24% Pretax MarginN/A Return on Equity-112.52% Return on Assets-2.79% Debt Debt-to-Equity Ratio18.95 Current Ratio0.90 Quick Ratio0.96 Sales & Book Value Annual Sales£12.61 million Price / Sales2.16 Cash FlowGBX 18.11 per share Price / Cash Flow4.31 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares34,850,000Free FloatN/AMarket Cap£27.18 million OptionableOptionable Beta1.04 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Matthew William Stork (Age 55)CEO & Director Comp: $342kMr. Stephen Daniel Symonds (Age 48)CFO & Exec. Director Comp: $203.31kMr. John HammondCo-FounderMr. Nick TaptiklisHead of Technology StrategyMs. Francesca Cormack Ph.D.Chief ScientistMr. Simon MerrittMarketing and Communications DirectorDr. Lisa Elizabeth Nolan Ph.D. (Age 61)VP Bus. Devel. Ms. Nicky AckerleyGlobal HR DirectorProf. Trevor RobbinsSr. ConsultantProf. Barbara Sahakian FMedSciFBPsS, Sr. ConsultantMore ExecutivesKey CompetitorsInduction Healthcare GroupLON:INHCTrellus HealthLON:TRLSFeedbackLON:FDBKIQ-AILON:IQAIRenalytixLON:RENXView All CompetitorsInsidersDebra LeevesBought 10,000 shares on 2/3/2023Total: £1.12 M ($112.00/share)View All Insider Transactions COG Stock - Frequently Asked Questions How have COG shares performed in 2023? Cambridge Cognition's stock was trading at GBX 114 at the beginning of 2023. Since then, COG stock has decreased by 31.6% and is now trading at GBX 78. View the best growth stocks for 2023 here. How were Cambridge Cognition's earnings last quarter? Cambridge Cognition Holdings Plc (LON:COG) posted its earnings results on Tuesday, September, 22nd. The company reported ($1.50) EPS for the quarter. Cambridge Cognition had a negative net margin of 3.24% and a negative trailing twelve-month return on equity of 112.52%. What other stocks do shareholders of Cambridge Cognition own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cambridge Cognition investors own include Interserve (IRV), Alio Gold Inc. (ALO.TO) (ALO), Concepta PLC (CPT.L) (CPT), IntelGenx Technologies (IGXT), Oxford Biomedica (OXB), Syneos Health (SYNH), Travelers Companies (TRV), Amryt Pharma (AMYT) and AltynGold (ALTN). What is Cambridge Cognition's stock symbol? Cambridge Cognition trades on the London Stock Exchange (LON) under the ticker symbol "COG." How do I buy shares of Cambridge Cognition? Shares of COG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Cambridge Cognition's stock price today? One share of COG stock can currently be purchased for approximately GBX 78. How much money does Cambridge Cognition make? Cambridge Cognition (LON:COG) has a market capitalization of £27.18 million and generates £12.61 million in revenue each year. How can I contact Cambridge Cognition? Cambridge Cognition's mailing address is Tunbridge Court Tunbridge Lane, Bottisham, CAMBRIDGE, CB25 9TU, United Kingdom. The official website for the company is www.cambridgecognition.com. The company can be reached via phone at 44 1223 810 700. This page (LON:COG) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cambridge Cognition Holdings Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.